New pill HRS-5041 tested in men with Tough-to-Treat prostate cancer

NCT ID NCT06830850

Recruiting now Disease control Sponsor: Atridia Pty Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental oral drug called HRS-5041 in 25 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has spread and no longer responds to standard hormone therapy. The main goal is to check the drug's safety and how the body processes it. Participants take the drug daily in 28-day cycles, and researchers will monitor side effects, vital signs, and lab results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-5041 (oral tablet)
What this could lead to: If it works, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a very early Phase 1 trial with only 25 participants, so the main goal is safety, not proof of effectiveness. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Cancer Research SA
RECRUITING

Adelaide, South Australia, Australia
Eastern Health (Box Hill Hospital)
RECRUITING

Melbourne, Australia
GenesisCare North Shore (Oncology)
RECRUITING

Sydney, New South Wales, Australia
Icon Cancer Centre South Brisbane
RECRUITING

Brisbane, Australia
Illawarra Shoalhaven Local Health District (Wollongong Hospital)
RECRUITING

Wollongong, Australia
John Flynn Private Hospital
RECRUITING

Brisbane, Australia
Linear Clinical Research Ltd
RECRUITING

Perth, Australia
MUPharm Pty Limited trading as Macquarie University Hospital Pharmacy
RECRUITING

Sydney, Australia
Macquarie University
RECRUITING

Sydney, Australia
Southern Oncology Clinical Research Unit
RECRUITING

Adelaide, South Australia, Australia
Sydney Adventist Hospital
RECRUITING

Sydney, New South Wales, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.